ProMetic Life Sciences Inc. (PLI) 2012年年度报告「TSX」.pdf

1、We believein our values and visionANNUAL REPORT 2012We believein our values and visionWe haveapplications and products utilizing prometics technologies already approvedapplications in development nearing scale-up and product approval stages+14+28Our Intellectual property patent portfolio comprises 1

2、92 issued patents,36 of which were granted in 2012 and 155 pending applications that are covered in more than 50 countries2PROMETIC LIFE SCIENCES INC.2012 EXECUTIVE SUMMARY2012 was a fruitful year for ProMetic on many different fronts:It was a year in which the Corporation successfully continued to

3、put in place the necessary conditions to achieve the next stage of its growth.The Corporation has,as planned,significantly improved its overall financial performance delivering in excess of its projected$21 million of revenues on its base case.This,combined with the strategic equity investment made

4、by Shenzhen Hepalink Pharmaceutical Co.,Ltd.(“Hepalink”),has had the direct result of improving its key financial metrics and has provided funds for projects that will support future growth.A growing number of transactions and strategic partnerships were secured impacting directly on the 2012 result

5、s and more importantly laying the foundation for sustainable growth into the future.The commercial opportunities being sought by the business development team continued to be focused on those which will provide a long-term annuity revenue stream to the business.The Corporation has seen its technolog

6、ies play an important role in allowing several of its clients product development programs to confidently move forward in 2012.In addition,ProMetic continued to add to its solid pipeline of business through new strategic partnerships as a result of the numerous commercial advantages provided by its